Drug Development

  • In a study of mRNA-based COVID-19 vaccine doses given at Stanford Medicine, vaccine allergies were rare, mild and mostly triggered by a vaccine additive, not the mRNA.

  • Once-nightly narcolepsy drug is effective

    A phase 3 study has found that an extended-release version of sodium oxybate reduces daytime sleepiness and attacks of muscle weakness in narcolepsy patients.

  • Endocannabinoids and epilepsy

    Release of the brain’s equivalent of THC, marijuana’s active component, reduces seizure activity but leads to post-seizure oxygen deprivation in the brain, Stanford scientists and their collaborators have shown.

  • Schulman on value of new Alzheimer’s drug

    The Food and Drug Administration has approved a new and expensive medication for Alzheimer’s disease, but it’s not clear it helps. Researcher Kevin Schulman discusses what the government should consider before deciding to cover it.

  • COVID-19 antibody treatment now available

    An infusion of monoclonal antibodies can ease COVID-19 symptoms and reduce complications in recently diagnosed, non-hospitalized people at high risk. Now people can refer themselves.

  • Drug enables scarless healing

    Researchers have identified the mechanism of scar formation in skin and demonstrated in mice a way to make wounds heal with normal skin instead of scar tissue.

  • Drug Discovery Symposium runs April 19-20

    The annual conference will feature an interdisciplinary cast of researchers, industry leaders and policymakers who will discuss advances in therapeutics, including COVID-19 treatments.

  • Purifying antibiotic could reduce its risk to hearing

    Scientists have discovered a simple method of reformulating gentamicin, a commonly used and highly effective antibiotic, that could reduce the risk it poses of causing deafness.

  • $14.3 million to develop broad-spectrum drugs

    The Stanford researcher is pursuing antiviral drugs with broad efficacy against enteroviruses, which cause common colds and polio, and coronaviruses including the one that causes COVID-19.

  • Subset of cells drive cancer growth

    Specialized cells at the leading edge of growing skin cancers dampen immune response and promote cancer invasion, Stanford researchers find. Targeting these cells could lead to effective therapies.

  • COVID-19 drug for outpatients tested

    Scientists at Stanford Medicine are investigating whether a molecule called interferon-lambda can help people with mild cases of COVID-19 feel better and reduce their transmission of the disease-causing virus.

  • Emergency approval of remdesivir for COVID-19

    Stanford Medicine researchers who participated in two separate clinical trials are encouraged by data indicating that remdesivir can treat COVID-19.


Related Websites